title: Potential Biomarkers for the Diagnosis of Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema.
abstract: BACKGROUND
  Angiotensin-converting enzyme inhibitor-induced angioedema (ACEi-AE) is the most frequent drug-induced angioedema. The aim of this study was to evaluate potential biomarkers for the detection of the risk to develop an ACEi-AE.
  
  
  METHODS
  Adult patients who started antihypertensive treatment with ramipril were included and followed up for 4-6 weeks. At baseline, 3 days, and 4-6 weeks after onset of therapy, blood samples were obtained.
  
  
  RESULTS
  Twenty-four patients could be enrolled. The thromboxane values were very heterogeneous, and none of the group differences observed was statistically significant. The values obtained for 6-keto-prostaglandin F1α (6-keto-PGF1α) showed a statistically significant increase with 10 mg/day doses under ramipril therapy.
  
  
  CONCLUSIONS
  In this small patient population, it could be shown that determination of 6-keto-PGF1α is feasible. It may prove to be a valuable blood marker for assessing the risk of developing ACEi-AE.
authors.affiliation: Hals-, Nasen- und Ohrenklinik, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
authors.forename: Murat
authors.initials: M
authors.lastname: Bas
authors.forename: Katharina
authors.initials: K
authors.lastname: Storck
authors.forename: Ulrich
authors.initials: U
authors.lastname: Strassen
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood*; D000368:Aged; D000799:Angioedema / Q000097:blood* / Q000139:chemically induced* / Q000628:therapy; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D015331:Cohort Studies; D005260:Female; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D017257:Ramipril / Q000009:adverse effects* / Q000627:therapeutic use; D012189:Retrospective Studies; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D015415:Biomarkers; D015121:6-Ketoprostaglandin F1 alpha; D017257:Ramipril